



Screening the Anticancer Activity, Cytotoxicity and Anti-Osteoarthritic Activity of Drynaria Quercifolia through Saos2 Cell Line Studies

Lakshman RR¹, Vasanth S¹, Bupesh G^{2*}, Balachandar V³, Saravanan KM⁴

¹Bio Medical Sciences Lab, Bharath Institute of Higher Education and Research, Chennai, India

²Natural Products and Tribal Health Research, Department of Forestry, Nagaland University, Zunheboto, Nagaland, India

³Stem cell and Regenerative Medicine/Translational Research, Department of Zoology, Central University of Punjab (CUPB), Bathinda, Punjab, India

⁴Department of Biotechnology, Bharath Institute of Higher Education and Research, Chennai, Tamilnadu, India

ABSTRACT

In the present work, we investigated cytotoxicity activity against SAOS2 cell lines, *Drynaria quercifolia*, a medicinal plant having the elements of a Southern India recipe for cancer therapy, was chosen. The MTT assay was performed to determine the cell type's cytotoxic activity. After testing several concentrations in three different plant extracts, such as methanol, ethanol and aqueous extracts against cell lines, the active plant extracts were diluted and tested for calculating IC₅₀. Plant extracts (*D. quercifolia*) demonstrated specific activity against cancer and osteoarthritic cell lines as compared to normal cells and should be explored further for active chemicals.

Keywords: Medicinal plants, *Drynaria quercifolia*, Anti-cancer activity, Cytotoxicity, Antiosteoarthritic activity

HOW TO CITE THIS ARTICLE: Lakshman RR, Vasanth S, Bupesh G, Balachandar V, Saravanan KM, Screening the Anticancer Activity, Cytotoxicity and Anti-Osteoarthritic Activity of *Drynaria Quercifolia* through Saos2 Cell Line Studies, J Res Med Dent Sci, 2023, 11 (2): 241-243.

Corresponding author: Giridharan Bupesh

e-mail ✉: bupeshgiri@nagalanduniversity.ac.in

Received: 25-January-2023, Manuscript No. jrmds-23-89588;

Editor assigned: 28-January-2023, PreQC No. jrmds-23-89588(PQ);

Reviewed: 11-February-2023, QC No. jrmds-23-89588(Q);

Revised: 16-February-2023, Manuscript No. jrmds-23-89588(R);

Published: 23-February-2023

INTRODUCTION

Chemical synthesis or isolation from natural sources can be used to obtain these therapeutic drug molecules [1,2]. Regarding the overall success rate in drug discovery, chemicals from botanical sources are more effective [3-5]. Countries such as India, Africa, and China have a long history of well-documented traditional medicine [6]. The initial listing of prospective species for biological activity screening is an essential procedure to proceed further [7,8]. When the biological activity of the plant is known from its traditional use, this strategy can be used [9,10]. This method aims to identify the chemicals that cause the activity based on their biological activity. *Drynaria quercifolia* belonging to the Polypodiaceae family, is one such plant that has been used in India for centuries to cure inflammation, rheumatism, headaches, bone fractures, jaundice, and other ailments [11]. The

epiphytic fern has a slender, fleshy, spreading rhizome heavily covered in soft reddish-brown scales.

D. quercifolia has been used to treat Tuberculosis, fever, dyspepsia, and cough. This medicine has been traditionally used in the treatment of diarrhoea, typhoid, cholera, jaundice, fever, headaches, skin ailments, and syphilis in the past [12]. The plant has also been discovered to help strengthen and heal sinews, muscles, and bones. *Drynaria* is used in a different medicinal combination to treat rheumatism [13,14]. Traditional Chinese medicine uses *Drynaria* rhizome topically to promote hair growth and cure baldness and is also used to treat hyperthyroidism [15]. Pain from traumatic injuries, such as sprains and contusions with bruising and swelling, is treated with *D. quercifolia* and various herbal combinations [16, 17]. Considering all the above, we have screened the therapeutic activity of plants by using MTT assay (a calorimetric assay to measure cell metabolic activity) and phase contrast microscopy (cell culture and live cell imaging).

MATERIALS AND METHODS

MTT assay

The MTT assay is a colorimetric, quantitative method for determining cell survival and growth. The metric being

measured is the metabolic activity of living cells. After Solubilization with DMSO, metabolically active cells convert pale yellow tetrazolium salt (MTT) to a purple water-insoluble formazan product that can be easily measured. The absorbance from the formazan product formed directly correlates with the number of viable cells. Osteosarcoma cell line (Saos2) Cells (50 X 103) were seeded in a 24-well plate and treated with various doses of *D. Quercifolia* extracts (DQE) at varied periods. After washing with PBS, the cells were treated with MTT (0.5 mg/mL) in DMEM (without phenol red) for 4 hours at 37 °C. The medium was removed, and the resulting formazan product was dissolved in DMSO. A multimode plate reader (Thermo Fischer, USA) was used to measure absorbance at 570 nm and 650 nm for measuring cell survival and background, respectively. The studies were carried out in triplicate, with the percentage of live cells calculated compared to the control group. Statistical analysis of three independent experiments and calculation of IC50 were performed using Graphpad Prism version 5 for Windows (Graphpad Prism Software, USA).

Phase contrast microscopy

The morphology of the Saos2 cells was directly observed using inverted phase contrast microscopy (Nikon Eclipse TS 100).

RESULTS

Anticancer activity measured by MTT assay

The viability of Saos2 cells in the presence of *D. quercifolia* extracts with different chemicals like ethyl-acetate, methanol, hexane and water was investigated using an MTT assay.

The ability of *D. quercifolia* extracts to cause toxicity towards Saos2 cells was assessed by MTT assay. When

the cells were exposed to different concentrations of *A. D. Quercifolia* extracts a very significant decrease in viability was observed. Treatment with 3.2 µg/mL of EA extract decreased the viability to 53 % at 24 h. When treated with a similar concentration of MeOH extract and H2O extract *D. Quercifolia* for 24 h, the viability was observed at 30.02 % and 28.15 %, respectively. 50 % toxicity was observed in the treatment of only 25 µg/mL of MeOH extract and H2O extract at 24 h. The maximum level of toxicity was observed in Saos2 cells treated with 250 µg/mL of all the *D. Quercifolia* extracts at 24h.

The IC50 values obtained were IC50 were compared with the positive control doxorubicin drug. Figure 1 showed a-Cell Control Saos2, b-Methanolic DQE (21.815µg), c-HexaneDQE (32.120µg), d-Aqueous DQE (25.55µg), e-Ethyl acetate (18.52µg), f-Doxorubicin (11.24µg) respectively. The anticancer activity of Saos2 cells in the figure revealed that the ethyl acetate and methanolic extract obtained the anticancer activity in a dose-dependent manner.

Phase contrast microscopy

Phase contrast microscopy is a simple and easy method to compare the morphological changes in normal and




Figure 1: Cytotoxicity of *D. Quercifolia* extracts in SAOS2 cell lines by MTT assay.




Figure 2: Cytotoxicity (IC50) of *D. Quercifolia* extracts (DQE) in osteosarcoma cell line SAOS2.

treated cells (Figure 2). Control Saos2 cells showed typical growth patterns with smooth and flattened cells, which were well separated and spread throughout the plate. They had a large nucleus with many spherical nucleoli. When treated with different extracts of *D. quercifolia* induced changes in their morphology. Even 25.55µg of Aqueous DQE induced the development of cytoplasmic blebs at the periphery of the cell cluster at 24 h. Membrane dissolution was observed in a few regions when treated with 32.120µg of Hexane DQE and 18.52µg of Ethyl acetate (Figure 2). When treated with 21.815µg of Methanolic DQE, cells formed vacuoles and drastic membrane damage at 24 h. After treatment with Doxorubicin (11.24µg) at 24 h, the shrinkage of cytoplasm, cells got rounded off, and detachment of cells from the substratum with dense regions was observed (Figure 2).

CONCLUSION

The tribal people of India, Africa and China use *D. quercifolia* as a medicinal plant. In the present study, we evaluate the cytotoxicity of *D. Quercifolia* by MTT assay and phase contrast microscopy. The plant extracts were very promising in showing anticancer, cytotoxicity, and anti-osteoarthritic potential. The findings of this study add some weight to the fern's supposed therapeutic properties. This plant has a lot of medicinal promise, but more study is needed to extract bioactive components and figure out what's going on.

REFERENCES

1. Saravanan KM, Zhang H, Senthil R, et al. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. *J Biomol Struct Dyn* 2022; 40:1970-1978.
2. Saravanan KM. The practice of remdesivir for treating covid-19 during pandemic. 2022; 1:65-68.
3. Vijayaram S, Kannan S, Saravanan KM, et al. Preliminary phytochemical screening, Antibacterial potential and GCMS analysis of two medicinal plant extracts. *Pak J Pharm Sci* 2016; 29:819-822.
4. Pothiaraj G, Manoranjani M, Pitchaikani S, et al. Investigation of therapeutic and immunomodulatory activity of Bacopa saponin from Bacopa monnieri. *South African J Bot* 2022; 151:639-650.
5. APB B, Bhuvaneswari S, Raj L, et al. A review on the potential species of the zingiberaceae family with antiviral efficacy towards enveloped viruses. *J Pure Appl Microbiol* 2022; 16:796-813.
6. Sen S, Chakraborty R. Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future. *J Tradit Complement Med* 2017; 7:234-244.
7. Zhang H, Yang Y, Li J, et al. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication *in vitro*. *PLOS Comput Biol* 2020; 16:e1008489.
8. Le HTT, Murugesan A, Ramesh T, et al. Molecular interaction of HIC, an agonist of P2Y1 receptor, and its role in prostate cancer apoptosis. *Int J Biol Macromol* 2021; 189:142-150.
9. Sen S, Chakraborty R, De B. Challenges and opportunities in the advancement of herbal medicine: India's position and role in a global context. *J Herb Med* 2011; 1:67-75.
10. Sundaram KKM, Bupesh G, Saravanan KM. Instrumentals behind embryo and cancer: A platform for prospective future in cancer research. *AIMS Mol Sci* 2022; 9:25-45.
11. Prasanna G, Anuradha R. A comprehensive review on phytopharmacological activities of *drynaria quercifolia* L. *Int J Pharmacogn Phytochem Res* 2016; 12-24.
12. Ramesh N, Viswanathan M, Saraswathy A, et al. Phytochemical and antimicrobial studies on *Drynaria quercifolia*. *Fitoterapia* 2001; 72:934-936.
13. Sujin RM, Jeeva S, Subin RM. Phytochemical and pharmacological studies of oak leaf fern, *drynaria quercifolia* (L.) j sm: A review. *Phytochem Pharmacol* 2021; 373-387.
14. Saravanan KM, Krishnaswamy S. Analysis of dihedral angle preferences for alanine and glycine residues in alpha and beta transmembrane regions. *J Biomol Struct Dyn* 2015; 33:552-562.
15. Pawar DV, Chandrashekar DKT, Mishra DR, et al. *Drynaria quercifolia* plant extract as a bone regenerative material in the treatment of periodontal intrabony defects: Clinical and radiographic assessment. *J Dent Med Sci* 2017; 16:93-99.
16. Karthikeyan V. Pharmacognostical standardization and phytochemical profile of rhizomes of *Drynaria quercifolia* (Linn). *Eur J Biomed Pharm Sci* 2016; 3:278-284.
17. Saravanan KM, Selvaraj S. Performance of secondary structure prediction methods on proteins containing structurally ambivalent sequence fragments. *Biopolymers* 2013; 100.